MemoProve / N-PEP-12

What MemoProve is

MemoProve contains N-PEP-12, a proprietary, heterogeneous mixture of low-molecular-weight peptides and free amino acids produced by standardized enzymatic proteolysis of purified porcine brain proteins. It was developed from the same product lineage as Cerebrolysin, but it is an oral tablet rather than an injectable preparation. N-PEP-12 is not one defined peptide, and the exact peptide identities, amino-acid proportions, and molecular-weight distribution are not publicly disclosed.

The active amount is 90 mg, not 425 mg

The commercial film-coated tablet contains 90 mg of N-PEP-12. The 425 mg figure used in some retail catalog titles refers to the mass of the complete tablet, not the N-PEP-12 amount. The planned exposure therefore records one whole tablet as 90 mg of N-PEP-12; it does not treat 425 mg as the active dose.

The strongest direct evidence is a 2026 randomized trial

A randomized, double-blind, placebo-controlled trial enrolled 276 adults aged 50 to 75 who reported cognitive complaints but did not have clinically significant impairment. Participants received placebo, 45 mg/day of N-PEP-12, or 90 mg/day and were evaluated at baseline and days 30, 90, and 180. The primary outcomes were computerized alertness, working-memory, and divided-attention tasks. Digit Span, stress, mood, sleep quality, and general health measures were secondary outcomes.

The result was promising, not a clean across-the-board win

The combined repeated-measures analysis found a significant group-by-visit interaction and improvement over time, but not a significant overall treatment-arm main effect. Exploratory day-90 comparisons favored both active groups on alertness, omission errors in divided attention and working memory, and forward and backward Digit Span. That is a useful efficacy signal, but the endpoint-by-endpoint findings should not be read as if every prespecified measure produced an independent definitive result.

Day 90 is the important evidence boundary

The randomized placebo comparison ended at day 90. The original placebo group then switched to 90 mg/day, leaving all participants on active product through day 180. Reported changes were most evident by day 90 and generally appeared to plateau afterward, but the extension cannot establish continued efficacy against placebo. This is why one 30-day retail pack is an early checkpoint rather than a complete experiment and why the proposed exposure lasts 90 days.

Earlier studies support plausibility but remain small

A 2005 double-blind trial randomized 54 adults aged 50 or older with age-related memory complaints to N-PEP-12 or placebo for 30 days. The active group improved on several memory and clinical-rating measures, but not every test. A separate acute study used a single 180 mg dose in healthy older adults and reported EEG and selected memory changes six hours later. Neither small study establishes durable enhancement in an unimpaired person, and the acute 180 mg exposure is not the basis of this protocol.

Applicability to this experiment is uncertain

The best trial applies most directly to adults aged 50 to 75 who already reported cognitive concerns, even though their screening scores did not show significant impairment. It does not establish enhancement in a younger or asymptomatic person. Studies in stroke and other neurological populations are even less transferable. The personal question is therefore narrow: does the commercial oral product produce a repeatable change in observable cognitive performance under otherwise stable conditions?

Current-stack context

MemoProve overlaps conceptually with the active Cerebrolysin experiment and would be impossible to interpret if the two were run together. It will wait until that course is closed and observations are no longer changing. Bromantane, Modafiendz, caffeine and the pre-workout routine already affect mood, alertness, or performance; if they remain in the routine, their exposure and timing must stay fixed rather than being added, removed, or adjusted during this test.

Safety evidence and its limits

Through day 90 of the 2026 trial, investigators reported 20 adverse events: seven with placebo, eight with 45 mg, and five with 90 mg. All were described as mild or moderate, none were judged related to treatment, and no severe or serious event was reported. Eight participants withdrew because of adverse events across the study. Reassurance remains limited because events were collected through open questioning rather than a systematic symptom inventory, the active mixture is not fully disclosed, and interaction data for a complex performance stack are thin.

Funding and disclosure context

The 2026 trial was funded by the Foundation for the Study of Nanoneurosciences and Neuroregeneration, and EVER Neuro Pharma supplied the product. The paper also disclosed that the principal investigator had served as principal investigator in Cerebrolysin trials. Those relationships do not invalidate the randomized data, but they belong in the interpretation of a manufacturer-linked, proprietary preparation.

Research question

Across 90 continuous days, does 90 mg/day of oral N-PEP-12 produce a repeatable improvement in sustained attention or working memory, supported by better mental clarity, lower cognitive fatigue, or more consistent focused work, without worsening sleep, anxiety, mood stability, or general tolerability?

Cycle and total extent

• Days -14 to -8: stable baseline and test familiarization.
• Days -7 to -1: scored comparison baseline.
• Days 1 to 90: continuous MemoProve exposure.
• Days 91 to 118: off-product observation.

The complete record lasts 132 days, or about 19 weeks. The final 28 days are an observational follow-up, not a validated pharmacologic washout period.

Proposed exposure

The proposed exposure is one whole commercial tablet containing 90 mg of N-PEP-12 once daily for 90 days, taken at the same time after the daily large meal. The timing is for repeatability, not a claim about an established absorption peak. There is no loading phase, titration, improvised tablet splitting, or simultaneous citicoline phase. This records a personal candidate protocol; it is not a suggested dose or instruction to use the product.

Start conditions and confounder control

The experiment begins only after Cerebrolysin is finished, its observations have stabilized, and two weeks of normal routine can be recorded. Sleep schedule, training rotation, calorie intake, and the established cognition-related stack should stay as stable as practical. Cortexin, Semax, citicoline, alpha-GPC, TAK-653, oxiracetam, and other new cognitive interventions should not start during the baseline, active phase, or follow-up. Any unavoidable medication, supplement, sleep, illness, or workload change must be annotated rather than silently absorbed into the result.

Daily observations

At the same pre-dose time each day, record morning alertness, mental clarity, cognitive fatigue, mood stability, stress tolerance, and sleep quality on fixed 0-to-10 scales. Also record sleep duration, awakenings, caffeine and pre-workout exposure, unusual workload or stress, and any adverse symptom. A short note should capture whether focused work felt easier, unchanged, or harder than usual.

Objective cognitive battery

Use the same brief psychomotor-vigilance or reaction-time task, the same backward Digit Span task, and the same divided-attention task throughout. Complete the battery on the same device, in the same setting and post-dose time window, with caffeine, food, and training timing held as constant as practical. The first baseline week is practice; those scores do not count. The second baseline week establishes the comparison range, followed by two scheduled batteries each week through day 90 and one each week during follow-up.

Real-world outcome

Choose one practical measure before the baseline begins and keep it unchanged: completed uninterrupted focus blocks, focused-work time, or another consistently recorded unit of cognitively demanding output. It is supportive rather than primary, but it prevents a small test-score movement from being mistaken for a meaningful daily result.

Review points

Review adherence, tolerability, and measurement quality at days 30, 60, and 90 without changing the dose. Day 30 can identify an early signal or a reason to stop, but absence of a day-30 effect is not a failed experiment because the strongest controlled evidence became clearest at day 90.

Success rule

MemoProve earns a positive result only if at least one fixed attention or working-memory measure improves beyond the established baseline variability, the change persists through most of the final four active weeks, and at least one real-world cognition measure moves in the same direction. The improvement must occur without a meaningful sleep, anxiety, mood, or tolerability penalty. A vague early feeling or novelty effect without objective and practical support counts as no clear signal.

Stop conditions

Persistent headache, agitation, anxiety, insomnia, mood deterioration, allergic symptoms, gastrointestinal problems, or a new neurological change would trigger reassessment and, if meaningful or persistent, end the active phase. A serious or acute symptom is a medical issue rather than an experiment datapoint.

What happens after day 90

Stop after day 90 and continue the same measurements for four weeks to see whether any apparent benefit persists, fades, or was simply part of the underlying trend. There is no evidence-backed reason to use repeated 30-days-on, 30-days-off cycles or to make MemoProve an automatic permanent stack item. A repeat would be considered only after a clear first result and a separate review of burden and uncertainty.

Sources

• Mureșanu et al., Nutrients, 2026 — randomized, double-blind trial of placebo, 45 mg/day, and 90 mg/day of N-PEP-12 in 276 adults with subjective cognitive complaints.
• ISRCTN10514154 — trial registration and protocol record for the 2026 randomized study.
• Windisch et al., Journal of Neural Transmission, 2005 — 30-day randomized, double-blind study in 54 older adults with age-related memory complaints.
• Griessbach et al., Neuropsychobiology, 2005 — acute 180 mg N-PEP-12 study measuring EEG and memory outcomes in healthy older adults.
• Guekht et al., Stroke, 2021 — post-stroke N-PEP-12 evidence, included as disease-population context rather than evidence of healthy cognitive enhancement.
• EVER Pharma: MemoProve — manufacturer product description and the 90 mg N-PEP-12 amount per tablet.
• RXELI catalog listing — the 425 mg retail-title figure that must not be confused with the 90 mg active N-PEP-12 amount.